Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;44(4):579-584.
doi: 10.1007/s13318-019-00543-1.

Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration

Affiliations
Free PMC article

Influence of Obesity and Type 2 Diabetes Mellitus on the Pharmacokinetics of Tramadol After Single Oral Dose Administration

Joanna Porażka et al. Eur J Drug Metab Pharmacokinet. .
Free PMC article

Abstract

Background and objectives: The number of overweight, obese and diabetic patients is constantly increasing. Metabolic disorders may affect the pharmacokinetics of drugs, e.g., by altering the activity of cytochrome P450 (CYP) isoenzymes. Tramadol is a commonly used analgesic metabolised mainly via CYP2D6 to its active metabolite, O-desmethyltramadol. The aim of the study was to assess the influence of overweight, obesity and type 2 diabetes mellitus on tramadol and O-desmethyltramadol pharmacokinetics.

Methods: All patients received a single oral dose (100 mg) of tramadol. The plasma concentrations of tramadol and O-desmethyltramadol were measured with the validated high-performance liquid chromatography method with fluorescence detection. The pharmacokinetic parameters of tramadol and O-desmethyltramadol were calculated by non-compartmental methods.

Results: After nephrectomy, the patients were divided into four groups-a control group (n = 12, mean [SD] age 61 [14] years, body mass index (BMI) 22 [2] kg/m2, CLcr (creatinine clearance) 74 [30] mL/min); an overweight group (n = 15, mean [SD] age 63 [11] years, BMI 27 [1] kg/m2, CLcr 81 [35] mL/min); an obese group (n = 12, mean [SD] age 57 [8] years, BMI 33 [4] kg/m2, CLcr 113 [51] mL/min); and an obese and diabetic group (n = 9, mean [SD] age 64 [10] years, BMI 33 [4] kg/m2, CLcr 87 [35] mL/min). Apart from the time to first occurrence of maximal concentration (tmax), there were no significant differences in the pharmacokinetic parameters of tramadol and O-desmethyltramadol among the groups. Moreover, there were no significant differences in the O-desmethyltramadol/tramadol ratios among the four groups of patients after nephrectomy.

Conclusions: No significant differences were found in the pharmacokinetics of tramadol and O-desmethyltramadol, indicating that the opioid can be administered to overweight, obese and diabetic patients without dosage adjustment.

Conflict of interest statement

Joanna Porażka, Edyta Szałek, Wojciech Połom, Mateusz Czajkowski, Tomasz Grabowski, Marcin Matuszewski, Edmund Grześkowiak have no confict of interest.

Figures

Fig. 1
Fig. 1
The tramadol plasma concentration–time profile following single oral administration of 100 mg of tramadol to patients after nephrectomy
Fig. 2
Fig. 2
The O-desmethyltramadol plasma concentration–time profile following singe oral administration of 100 mg of tramadol to patients after nephrectomy

Similar articles

See all similar articles

Cited by 1 article

References

    1. World Health Organization. Global report on obesity. 2016. http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1. Accessed 8 Feb 2018.
    1. World Health Organization. Fact sheet on obesity and overweight. 2018. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 8 Feb 2018.
    1. Brill M, Diepstraten J, van Rongen A, van Kralingen S, van den Anker J, Knibbe K. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277–304. doi: 10.2165/11599410-000000000-00000. - DOI - PubMed
    1. Dostałek M, Akhlagh F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51:481–499. doi: 10.1007/BF03261926. - DOI - PubMed
    1. De Hoogd S, Valitalo PA, Dahan A, van Kralingen S, Coughtrie M, van Dongen E, van Ramshorst B. Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide. Clin Pharmacokinet. 2017;56:1577–1587. doi: 10.1007/s40262-017-0544-2. - DOI - PMC - PubMed
Feedback